CoChat

Association of perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study

Open access
Borghese, Michael M., Walker, Mark, Helewa, Michael E., Fraser, William D., Arbuckle, Tye E. · 2020 · Environment International
Cited by 79

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Perfluoroalkyl substances (PFAS) have been linked with a number of developmental, reproductive, hepatic, and cardiovascular health outcomes. However, the evidence for an association between PFAS and hypertensive disorders of pregnancy (including gestational hypertension and preeclampsia) is equivocal and warrants further investigation. OBJECTIVES: To examine the relationship between background levels of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), and perfluorohexane sulfonate (PFHxS) and the development of gestational hypertension or preeclampsia in a Canadian pregnancy cohort. We also explored the potential for effect modification according to fetal sex. METHODS: Maternal plasma samples were collected in the first trimester from participants in the MIREC study and were analyzed for PFOA, PFOS, and PFHxS. Blood pressure was measured during each trimester. Gestational hypertension and preeclampsia were defined using the Society of Obstetricians and Gynaecologists of Canada guidelines. Logistic regression models were used to derive adjusted odds ratios (OR) and 95% confidence intervals (CI) for associations between PFAS concentrations (per doubling of concentration as well as according to tertiles) and gestational hypertension or preeclampsia. Linear mixed models were used to examine the association between PFAS concentrations and changes in blood pressure throughout pregnancy. RESULTS: Data from 1739 participants were analyzed. 90% of women were normotensive throughout pregnancy, 7% developed gestational hypertension without preeclampsia, and 3% developed preeclampsia. In the full analyses, neither PFOA nor PFOS were associated with gestational hypertension or preeclampsia. However, each doubling of PFHxS plasma concentration was associated with higher odds of developing preeclampsia (OR = 1.32; 95% CI: 1.03, 1.70). In addition, participants in the highest PFHxS tertile (1.4-40.0 μg/L) had higher odds of developing preeclampsia relative to those in the lowest tertile (OR = 3.06; 95% CI: 1.27, 7.39). In stratified analyses, this effect was only apparent among women carrying a female fetus (OR = 4.90; 95% CI: 1.02, 22.3). However, among women carrying a male fetus, both PFOS and PFHxS were associated with gestational hypertension, but not preeclampsia. Higher plasma concentrations of all three PFAS were associated with increases in diastolic blood pressure throughout pregnancy, and PFOA and PFHxS were also associated with systolic blood pressure. Discrepant findings were similarly revealed in analyses stratified by fetal sex. CONCLUSIONS: Higher levels of PFHxS were associated with the development of preeclampsia, but not gestational hypertension. Neither PFOA nor PFOS were associated with either outcome. However, we show, for the first time, that fetal sex may modify these associations, a finding which warrants replication and further study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.envint.2020.105789

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 53

  1. American College of Obstetricians and Gynecologists, 2002, Diagnosis and management of preeclampsia and eclampsia, Int. J. Gynaecol. Obstet., 77, 67, 10.1016/S0020-7292(02)80002-9 · DOI · Paper page
  2. Andersen, 2010, Prenatal exposures to perfluorinated chemicals and anthropometric measures in infancy, Am. J. Epidemiol., 172, 1230, 10.1093/aje/kwq289 · DOI · Paper page
  3. Arbuckle, 2013, Cohort profile: the maternal-infant research on environmental chemicals research platform, Paediatr. Perinat. Epidemiol., 27, 415, 10.1111/ppe.12061 · DOI · Paper page
  4. Ashley-Martin, 2016, Maternal and neonatal levels of perfluoroalkyl substances in relation to gestational weight gain, Int. J. Environ. Res. Public Health, 13, 10.3390/ijerph13010146 · DOI · Paper page
  5. Bach, 2015, Perfluoroalkyl and polyfluoroalkyl substances and human fetal growth: A systematic review, Crit. Rev. Toxicol., 45, 53, 10.3109/10408444.2014.952400 · DOI · Paper page
  6. Beesoon, 2012, Exceptionally high serum concentrations of perfluorohexanesulfonate in a Canadian family are linked to home carpet treatment applications, Environ. Sci. Technol., 46, 12960, 10.1021/es3034654 · DOI · Paper page
  7. Berg, 2014, Maternal serum concentrations of per- and polyfluoroalkyl substances and their predictors in years with reduced production and use, Environ. Int., 69, 58, 10.1016/j.envint.2014.04.010 · DOI · Paper page
  8. Brantsæter, 2013, Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women, Environ. Int., 54, 74, 10.1016/j.envint.2012.12.014 · DOI · Paper page
  9. Butalia, 2018, Hypertension Canada’s 2018 guidelines for the management of hypertension in pregnancy, Can. J. Cardiol., 34, 526
  10. Butenhoff, 2009, Evaluation of potential reproductive and developmental toxicity of potassium perfluorohexanesulfonate in Sprague Dawley rats, Reprod. Toxicol., 27, 331, 10.1016/j.reprotox.2009.01.004 · DOI
  11. Chappell, 2020, Assessment of the mode of action underlying the effects of GenX in mouse liver and implications for assessing human health risks, Toxicol. Pathol., 10.1177/0192623320905803 · DOI · Paper page
  12. Darrow, 2013, Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the Mid-Ohio Valley, 2005–2010, Environ. Health Perspect., 121, 1207, 10.1289/ehp.1206372 · DOI · Paper page
  13. Desquilbet, 2010, Dose-response analyses using restricted cubic spline functions in public health research, Statist. Med., 10.1002/sim.3841 · DOI · Paper page
  14. DiGiuseppe, 2002, Reliability of birth certificate data: a multi-hospital comparison to medical records information, Matern. Child Health J., 6, 169, 10.1023/A:1019726112597 · DOI · Paper page
  15. Fei, 2007, Perfluorinated chemicals and fetal growth: a study within the Danish national birth cohort, Environ. Health Perspect., 115, 1677, 10.1289/ehp.10506 · DOI · Paper page
  16. Fisher, 2016, Concentrations of persistent organic pollutants in maternal and cord blood from the maternal-infant research on environmental chemicals (MIREC) cohort study, Environ. Heal., 15, 59, 10.1186/s12940-016-0143-y · DOI · Paper page
  17. Fisher, 2013, Do perfluoroalkyl substances affect metabolic function and plasma lipids?—Analysis of the 2007–2009, Canadian Health Measures Survey (CHMS) Cycle 1, Environ. Res., 121, 95, 10.1016/j.envres.2012.11.006 · DOI
  18. Haines, 2017, Human biomonitoring reference values derived for persistent organic pollutants in blood plasma from the Canadian Health Measures Survey 2007–2011, Int. J. Hyg. Environ. Health, 220, 744, 10.1016/j.ijheh.2017.03.004 · DOI
  19. Houde, 2006, Biological monitoring of polyfluoroalkyl substances: a review, Environ. Sci. Technol., 40, 3463, 10.1021/es052580b · DOI · Paper page
  20. Hu, 2018, Can profiles of poly- and Perfluoroalkyl substances (PFASs) in human serum provide information on major exposure sources?, Environ. Health, 17, 11, 10.1186/s12940-018-0355-4 · DOI · Paper page
  21. Huang, 2019, Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive disorders of pregnancy, Environ. Health, 18, 5, 10.1186/s12940-018-0445-3 · DOI · Paper page
  22. Huppertz, 2008, Placental origins of preeclampsia: challenging the current hypothesis, Hypertension (Dallas, Tex. 1979), 51, 970, 10.1161/HYPERTENSIONAHA.107.107607 · DOI · Paper page
  23. Huppertz, 2003, Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation, Placenta, 24, 181, 10.1053/plac.2002.0903 · DOI · Paper page
  24. Jain, 2019, Perfluoroalkyl acids serum concentrations and their relationship to biomarkers of renal failure: Serum and urine albumin, creatinine, and albumin creatinine ratios across the spectrum of glomerular function among US adults, Environ. Res., 174, 143, 10.1016/j.envres.2019.04.034 · DOI · Paper page
  25. Jelin, 2009, Early-onset preeclampsia and neonatal outcomes, J. Matern. Neonatal Med., 23, 1
  26. Kärrman, 2006, Levels of 12 perfluorinated chemicals in pooled australian serum, collected 2002–2003, in relation to age, gender, and region, Environ. Sci. Technol., 40, 3742, 10.1021/es060301u · DOI · Paper page
  27. Lau, 2006, Effects of perfluorooctanoic acid exposure during pregnancy in the mouse, Toxicol. Sci., 90, 510, 10.1093/toxsci/kfj105 · DOI · Paper page
  28. Lewin, 2017, Univariate predictors of maternal concentrations of environmental chemicals: The MIREC study, Int. J. Hyg. Environ. Health, 220, 77, 10.1016/j.ijheh.2017.01.001 · DOI
  29. Lin, 2010, Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults, Am. J. Gastroenterol., 105, 1354, 10.1038/ajg.2009.707 · DOI · Paper page
  30. Liu, 2019, Structure-based investigation on the association between perfluoroalkyl acids exposure and both gestational diabetes mellitus and glucose homeostasis in pregnant women, Environ. Int., 127, 85, 10.1016/j.envint.2019.03.035 · DOI · Paper page
  31. Lo, 2013, Hypertensive disease of pregnancy and maternal mortality, Curr. Opin. Obstet. Gynecol., 25, 124, 10.1097/GCO.0b013e32835e0ef5 · DOI · Paper page
  32. Magee, 2014, Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens, Int. J. Women’s Cardiovasc. Heal., 4, 105
  33. Nakimuli, 2016, The burden of maternal morbidity and mortality attributable to hypertensive disorders in pregnancy: a prospective cohort study from Uganda, BMC Pregnancy Childbirth, 16, 205, 10.1186/s12884-016-1001-1 · DOI
  34. Nolan, 2010, Congenital anomalies, labor/delivery complications, maternal risk factors and their relationship with perfluorooctanoic acid (PFOA)-contaminated public drinking water, Reprod. Toxicol., 29, 147, 10.1016/j.reprotox.2009.10.012 · DOI · Paper page
  35. Papadopoulou, 2015, Reliability of perfluoroalkyl substances in plasma of 100 women in two consecutive pregnancies, Environ. Res., 140, 421, 10.1016/j.envres.2015.04.022 · DOI · Paper page
  36. Pijnenborg, 2006, The uterine spiral arteries in human pregnancy: facts and controversies, Placenta, 27, 939, 10.1016/j.placenta.2005.12.006 · DOI · Paper page
  37. Rosen, 2017, PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling, Toxicology, 387, 95, 10.1016/j.tox.2017.05.013 · DOI · Paper page
  38. Savitz, 2012, Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community, Epidemiology, 23, 386, 10.1097/EDE.0b013e31824cb93b · DOI · Paper page
  39. Savitz, 2012, Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio valley, Environ. Health Perspect., 120, 1201, 10.1289/ehp.1104752 · DOI · Paper page
  40. Shen, 2017, Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia, PLoS One, 12, e0175914, 10.1371/journal.pone.0175914 · DOI · Paper page
  41. Starling, 2014, Perfluoroalkyl substances during pregnancy and validated preeclampsia among nulliparous women in the Norwegian Mother and Child Cohort Study, Am. J. Epidemiol., 179, 824, 10.1093/aje/kwt432 · DOI · Paper page
  42. Steegers, 2010, Pre-eclampsia, Lancet, 376, 631, 10.1016/S0140-6736(10)60279-6 · DOI · Paper page
  43. Stein, 2009, Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome, Am. J. Epidemiol., 170, 837, 10.1093/aje/kwp212 · DOI · Paper page
  44. Stuart, 2013, Maternal recall of hypertensive disorders in pregnancy: a systematic review, J. Women’s Health, 22, 37, 10.1089/jwh.2012.3740 · DOI · Paper page
  45. Sundström, 2012, Comparative pharmacokinetics of perfluorohexanesulfonate (PFHxS) in rats, mice, and monkeys, Reprod. Toxicol., 33, 441, 10.1016/j.reprotox.2011.07.004 · DOI · Paper page
  46. van Esch, 2017, Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity, J. Matern. Neonatal Med., 30, 2789, 10.1080/14767058.2016.1263295 · DOI
  47. Vatten, 2004, Offspring sex and pregnancy outcome by length of gestation, Early Hum. Dev., 76, 47, 10.1016/j.earlhumdev.2003.10.006 · DOI · Paper page
  48. Velez, 2015, Maternal exposure to perfluorinated chemicals and reduced fecundity: the MIREC study, Hum. Reprod., 30, 701, 10.1093/humrep/deu350 · DOI · Paper page
  49. Wallis, 2008, Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004, Am. J. Hypertens., 21, 521, 10.1038/ajh.2008.20 · DOI · Paper page
  50. Wang, 2019, Efficiency of maternal-fetal transfer of perfluoroalkyl and polyfluoroalkyl substances, Environ. Sci. Pollut. Res., 26, 2691, 10.1007/s11356-018-3686-3 · DOI
  51. Wikström, 2019, Maternal serum levels of perfluoroalkyl substances in early pregnancy and offspring birth weight, Pediatr. Res., 1
  52. Wikström, 2019, Early pregnancy serum levels of perfluoroalkyl substances and risk of preeclampsia in Swedish women, Sci. Rep., 9, 9179, 10.1038/s41598-019-45483-7 · DOI · Paper page
  53. Ying, 2018, Hypertensive disorders of pregnancy and future maternal cardiovascular risk, J. Am. Heart Assoc., 7, e009382, 10.1161/JAHA.118.009382 · DOI · Paper page

Cited by

See all 79

Metadata

Authors
Borghese, M. M., Walker, M., Helewa, M. E., Fraser, W. D., & Arbuckle, T. E.
Venue
Environment International
Publisher
Elsevier BV
Published
2020-08
Volume
141
Pages
105789
ISSN
0160-4120 (ISSN-L)
OpenAlex
W3022808302
Cited by
79
References
15
FWCI
3.74
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Canadian Institutes of Health Research
  • Health Canada

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study. https://app.cochat.ai/papers/10.1016/j.envint.2020.105789
The paper
Borghese, M. M., Walker, M., Helewa, M. E., Fraser, W. D., & Arbuckle, T. E. (2020). Association of perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study. Environment International. https://doi.org/10.1016/j.envint.2020.105789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.